Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon α for advanced carcinoid tumors: FNCLCC-FFCD 9710

被引：80

作者：

Dahan, Laetitia ^{[1
]}

Bonnetain, Frank ^{[2
]}

Rougier, Philippe ^{[3
]}

Raoul, Jean-Luc ^{[4
]}

Gamelin, Eric ^{[5
]}

Etienne, Pierre-Luc ^{[6
]}

Cadiot, Guillaume ^{[7
]}

Mitry, Emmanuel

Smith, Denis ^{[8
]}

Cvitkovic, Frederique ^{[9
]}

Coudert, Bruno ^{[10
]}

Ricard, Floriane ^{[1
]}

Bedenne, Laurent ^{[1
]}

Seitz, Jean-Francois ^{[1
]}

机构：

[1] Univ Aix Marseille 2, CHU Timone, Hop Timone, Assistance Publ Hop Marseille, F-13385 Marseille 5, France

[2] FFCD, Dijon, France

[3] Hop Ambroise Pare, AP HP, Boulogne, France

[4] Ctr Eugene Marquis, Rennes, France

[5] Ctr Paul Papin, Angers, France

[6] Clin Armoricaine, St Brieuc, France

[7] Hop Robert Debre, Reims, France

[8] CHU Haut Leveque, Pessac, France

[9] Ctr Rene Huguenin, St Cloud, France

[10] Ctr Francois Leclerc, Dijon, France

来源：

关键词：

COOPERATIVE-ONCOLOGY-GROUP; NEUROENDOCRINE TUMORS; GASTROENTEROPANCREATIC TUMORS; LEUKOCYTE INTERFERON; MANAGEMENT; OCTREOTIDE; FLUOROURACIL; COMBINATION; DOXORUBICIN; THERAPY;

D O I：

10.1677/ERC-09-0104

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aim of this randomized multicenter phase III trial was to compare chemotherapy and interferon (IFN) in patients with metastatic carcinoid tumors. Patients with documented progressive, unresectable, metastatic carcinoid tumors were randomized between 5-fluorouracil plus streptozotocin (day 1-5) and recombinant IFN-alpha-2a (3 MU X 3 per week) Primary endpoint was progression-free survival (PFS) From February 1998 to June 2004, 64 patients were included The two arms were well matched for median age, sex ratio, PS 0-1, previous chemotherapy, surgery, or radiotherapy The median PFS for chemotherapy was 5 5 months versus 14 1 for IFN (hazard ratio = 0.75 (0.41-1 36)) Overall survival (OS), tolerance, and effects on carcinoid symptoms were not significantly different. Despite a trend in favor of IFN, there was no difference in PFS and OS in advanced metastatic carcinoid tumors and therapeutic effect of both treatments was mild. Endocrine-Related Cancer (2009) 16 1351-1361

引用

页码：1351 / 1361

页数：11

共 24 条

[1] Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors:: A randomized trial [J].

Arnold, R ;

Rinke, A ;

Klose, KJ ;

Müller, HH ;

Wied, M ;

Zamzow, K ;

Schmidt, C ;

Schade-Brittinger, C ;

Barth, P ;

Moll, R ;

Koller, M ;

Unterhalt, M ;

Hiddemann, W ;

Schmidt-Lauber, M ;

Pavel, M ;

Arnold, CN .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2005, 3 (08) :761-771

[2]

ARNOLD R, 2009, P AN M AM SOC CLIN, V27, P4508

[3]

*CONS SCI FFCD, 2003, GASTROENTEROLOGIE CL, V27, P43

[4] Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells [J].

Detjen, KM ;

Welzel, M ;

Farwig, K ;

Brembeck, FH ;

Kaiser, A ;

Riecken, EO ;

Wiedenmann, B ;

Rosewicz, S .

GASTROENTEROLOGY, 2000, 118 (04) :735-748

[5]

Dirix LY, 1996, ANTI-CANCER DRUG, V7, P175

[6] STREPTOZOCIN PLUS FLUOROURACIL VERSUS DOXORUBICIN THERAPY FOR METASTATIC CARCINOID-TUMOR [J].

ENGSTROM, PF ;

LAVIN, PT ;

MOERTEL, CG ;

FOLSCH, E ;

DOUGLASS, HO .

JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (11) :1255-1259

[7] Consensus guidelines for the management of patients with digestive neuroendocrine tumors -: Well-differentiated jejunal-ileal tumor/carcinoma [J].

Eriksson, Barbro ;

Kloeppel, Guenter ;

Krenning, Eric ;

Ahlman, Hakan ;

Ploeckinger, Ursula ;

Wiedenmann, Bertram ;

Arnold, Rudolf ;

Auernhammer, Christoph ;

Koerner, Meike ;

Rindi, Guido ;

Wildi, Stefan .

NEUROENDOCRINOLOGY, 2008, 87 (01) :8-19

[8] Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors -: The International Lanreotide and Interferon Alfa Study Group [J].

Faiss, S ;

Pape, UF ;

Böhmig, M ;

Dörffel, Y ;

Mansmann, U ;

Golder, W ;

Riecken, EO ;

Wiedenmann, B .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) :2689-2696

[9] Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin [J].

Gonzalez, MA ;

Biswas, S ;

Clifton, L ;

Corrie, PG .

BRITISH JOURNAL OF CANCER, 2003, 89 (03) :455-456

[10]

HALLER D, 1990, P AN M AM SOC CLIN, V9, P102

← 1 2 3 →